IL152785A0 - Compositions and methods for cell dedifferentiation and tissue regeneration - Google Patents

Compositions and methods for cell dedifferentiation and tissue regeneration

Info

Publication number
IL152785A0
IL152785A0 IL15278501A IL15278501A IL152785A0 IL 152785 A0 IL152785 A0 IL 152785A0 IL 15278501 A IL15278501 A IL 15278501A IL 15278501 A IL15278501 A IL 15278501A IL 152785 A0 IL152785 A0 IL 152785A0
Authority
IL
Israel
Prior art keywords
compositions
methods
tissue regeneration
cell dedifferentiation
dedifferentiation
Prior art date
Application number
IL15278501A
Other languages
English (en)
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of IL152785A0 publication Critical patent/IL152785A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15278501A 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration IL152785A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20408100P 2000-05-12 2000-05-12
US20408000P 2000-05-12 2000-05-12
US20408200P 2000-05-12 2000-05-12
PCT/US2001/015582 WO2001088103A2 (fr) 2000-05-12 2001-05-14 Compositions et procedes de dedifferenciation cellulaire et regeneration tissulaire

Publications (1)

Publication Number Publication Date
IL152785A0 true IL152785A0 (en) 2003-06-24

Family

ID=27394620

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15278501A IL152785A0 (en) 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration

Country Status (7)

Country Link
US (1) US20030212024A1 (fr)
EP (1) EP1318833A2 (fr)
JP (1) JP2004511209A (fr)
AU (2) AU6459801A (fr)
CA (1) CA2408701A1 (fr)
IL (1) IL152785A0 (fr)
WO (1) WO2001088103A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
CA2469370C (fr) 2001-12-07 2014-07-08 Macropore Biosurgery, Inc. Unite de traitement de cellule d'origine adipeuse
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
WO2006075986A1 (fr) * 2005-01-10 2006-07-20 Macropore Biosurgery, Inc. Appareil et procede de suivi, gestion et entretien de dispositifs medicaux
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US8105580B2 (en) * 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US20060204556A1 (en) * 2001-12-07 2006-09-14 Cytori Therapeutics, Inc. Cell-loaded prostheses for regenerative intraluminal applications
US7651684B2 (en) * 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US7595043B2 (en) * 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US20050282733A1 (en) * 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
AU2003303742A1 (en) * 2002-12-24 2004-11-04 Board Of Regents, The University Of Texas System Screening methods using zebrafish to identify thrombotic and anti-thrombotic compounds and genes
EP1622637A2 (fr) 2003-05-15 2006-02-08 The University of Chicago Procedes et compositions de regeneration nerveuse
WO2006071794A2 (fr) 2004-12-23 2006-07-06 Ethicon Incorporated Cellules postnatales derivees de tissus du cordon ombilical, et procedes de production et d'utilisation de celles-ci
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
EP1641913B1 (fr) 2003-06-27 2016-01-06 DePuy Synthes Products, Inc. Cellules postnatales derivees de tissu de cordon ombilical, et leur procede de production et d'utilisation
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
WO2005047524A2 (fr) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions et procedes pour induire la differenciation cellulaire
US20050232905A1 (en) * 2004-03-26 2005-10-20 Yeh Edward T Use of peripheral blood cells for cardiac regeneration
WO2006071778A2 (fr) 2004-12-23 2006-07-06 Ethicon Incorporated Traitement de la maladie de parkinson et de troubles associes au moyen de cellules derivees postnatales
EP1864132B1 (fr) 2005-03-31 2012-06-27 Stemnion, Inc. Compositions à base de cellules amniotiques, méthodes de production et utilisations desdites compositions
WO2007070870A1 (fr) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions et procedes d'inhibition d'une reponse immunitaire negative en transplantation avec defaut d'histocompatibilite
JP5179376B2 (ja) 2005-12-19 2013-04-10 エシコン・インコーポレイテッド ローラーボトルでの分娩後取り出し細胞の体外増殖
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
GB0613031D0 (en) * 2006-06-30 2006-08-09 Renovo Ltd Medicaments
NZ584827A (en) 2007-10-01 2012-10-26 Isis Pharmaceuticals Inc Antisense modulation of fibroblast growth factor receptor 4 expression
WO2009046335A1 (fr) 2007-10-05 2009-04-09 Ethicon, Incorporated Réparation et régénération du tissu rénal au moyen de cellules provenant de tissus de cordon ombilical humain
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
WO2010021993A1 (fr) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Procédés d'utilisation de cellules issues du tissu adipeux dans le traitement du système lymphatique et d'une maladie maligne
CN102387807A (zh) 2008-12-19 2012-03-21 先进科技及再生医学有限责任公司 肺部疾病和病症的治疗
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
US8722034B2 (en) 2009-03-26 2014-05-13 Depuy Synthes Products Llc hUTC as therapy for Alzheimer's disease
ES2625893T3 (es) 2009-05-01 2017-07-20 Bimini Technologies Llc Sistemas, procedimientos y composiciones para optimizar injertos enriquecidos con tejido y células
US8735116B2 (en) 2010-09-13 2014-05-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration High-density spot seeding for tissue model formation
EP2721156B1 (fr) 2011-06-16 2016-12-21 Ionis Pharmaceuticals, Inc. Modulation antisens de l'expression du récepteur 4 du facteur de croissance fibroblastique
JP6301263B2 (ja) 2011-12-23 2018-03-28 デピュイ・シンセス・プロダクツ・インコーポレイテッド ヒト臍帯組織由来細胞の検出
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
CN114207144A (zh) * 2019-05-28 2022-03-18 卡斯西部储备大学 用于保存dna甲基化的组合物和方法
CN116555346B (zh) * 2023-07-05 2023-09-01 中山大学 一种采用碳纳米管基因载体递送系统促进草鱼生长的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528265A (en) * 1982-05-11 1985-07-09 Becker Robert O Processes and products involving cell modification
PT716610E (pt) * 1993-08-26 2006-08-31 Genetics Inst Llc Proteinas morfogeneticas dos ossos de seres humanos para utilizacao em regeneracao neural
ATE311437T1 (de) * 1998-09-18 2005-12-15 Massachusetts Inst Technology Verwendung von wachstumsfaktoren und hormonen zur vermehrung menschlicher chondrozyten und knorpelgewebeherstellung
TW509699B (en) * 1998-09-24 2002-11-11 Chugau Pharmaceutical Co Ltd Ethylamine derivatives
US6897061B1 (en) * 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US7425448B2 (en) * 2001-07-12 2008-09-16 Geron Corporation Cardiomyocyte precursors from human embryonic stem cells
US20040014209A1 (en) * 2002-01-23 2004-01-22 Lassar Andrew B. Compositions and methods for modulating cell differentiation

Also Published As

Publication number Publication date
WO2001088103A9 (fr) 2002-05-23
US20030212024A1 (en) 2003-11-13
EP1318833A2 (fr) 2003-06-18
WO2001088103A2 (fr) 2001-11-22
JP2004511209A (ja) 2004-04-15
AU2001264598B2 (en) 2006-07-06
WO2001088103A3 (fr) 2003-03-13
CA2408701A1 (fr) 2001-11-22
AU6459801A (en) 2001-11-26

Similar Documents

Publication Publication Date Title
AU6459801A (en) Compositions and methods for cell dedifferentiation and tissue regeneration
EP1570069A4 (fr) Compositions et procedes de dedifferentiation cellulaire et de regeneration de tissus
EP1299068A4 (fr) Compositions dermatologiques soufrees et procedes de reduction des mauvaises odeurs dans des compositions dermatologiques
AU3459301A (en) Compositions and methods for performing biological reactions
EG23145A (en) Incontinence insert applicators and methods for their use
AU3387599A (en) Methods and compositions for tissue regeneration
AU5752601A (en) Splice-region antisense composition and method
AP2006003708A0 (en) Methods and compositions for treating flavivirusesand pestiviruses
EP1682150A4 (fr) Compositions et procedes pour induire la differenciation cellulaire
AU8911801A (en) Improved nanocomposite compositions and methods for making and using same
AU2778801A (en) Antisense compositions and methods
PL360185A1 (en) Compositions and methods for body weight management
AU7801601A (en) Cleaning composition and methods for manufacturing and using
AU2001253065A1 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins
AU6832101A (en) Composition and method
IL144517A0 (en) Compositions and methods for treating cataracts
PT1471902E (pt) Métodos para o tratamento da perda de audição
AU4163402A (en) Composition and method
HK1044172A1 (zh) 產生無分化的細胞的裝置和方法
AU2002213114A1 (en) Compositions and methods for reducing gnrh-induced bone loss
AU2001251391A1 (en) Compositions and methods for promoting neural regeneration
EP1351647A4 (fr) Compositions et methodes pour traiter l'hyperpigmentation
AU7262500A (en) Method and composition for dental bleaching
SG86407A1 (en) Regenerative tie-high tie-low cell
EP1395280A4 (fr) Composition et methodes modifiant l'absorption de metallo-corrinoides